Sharps Technology (STSS) Competitors

PolyPid (NASDAQ:PYPD) and Sharps Technology (NASDAQ:STSS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, community ranking, analyst recommendations and institutional ownership.

Does the MarketBeat Community favor PYPD or STSS?

PolyPid received 25 more outperform votes than Sharps Technology when rated by MarketBeat users. However, 100.00% of users gave Sharps Technology an outperform vote while only 76.47% of users gave PolyPid an outperform vote.

Company	Underperform	Outperform
PolyPid	Outperform Votes 26 76.47%	Underperform Votes 8 23.53%
Sharps Technology	Outperform Votes 1 100.00%	Underperform Votes No Votes

Does the media favor PYPD or STSS?

In the previous week, Sharps Technology had 2 more articles in the media than PolyPid. MarketBeat recorded 5 mentions for Sharps Technology and 3 mentions for PolyPid. PolyPid's average media sentiment score of 1.00 beat Sharps Technology's score of 0.87 indicating that PolyPid is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PolyPid	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sharps Technology	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has higher earnings and valuation, PYPD or STSS?

PolyPid is trading at a lower price-to-earnings ratio than Sharps Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$23.86M	-$12.64	-0.28
Sharps Technology	N/A	N/A	-$9.84M	-$0.60	-0.26

Do analysts recommend PYPD or STSS?

PolyPid currently has a consensus target price of $14.00, indicating a potential upside of 302.30%. Given PolyPid's higher possible upside, research analysts clearly believe PolyPid is more favorable than Sharps Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Sharps Technology	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Do insiders & institutionals have more ownership in PYPD or STSS?

26.5% of PolyPid shares are owned by institutional investors. Comparatively, 17.2% of Sharps Technology shares are owned by institutional investors. 24.7% of PolyPid shares are owned by company insiders. Comparatively, 12.6% of Sharps Technology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Is PYPD or STSS more profitable?

Sharps Technology's return on equity of -100.69% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-969.85%	-121.65%
Sharps Technology	N/A	-100.69%	-71.53%

Which has more volatility & risk, PYPD or STSS?

PolyPid has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500. Comparatively, Sharps Technology has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500.

Summary

PolyPid and Sharps Technology tied by winning 7 of the 14 factors compared between the two stocks.